| Identification | Back Directory | [Name]
SC-1 | [CAS]
1313019-65-6 | [Synonyms]
SC-1
SC-1 >=98% (HPLC)
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N′-[4-(4-cyanophenoxy)phenyl]-urea
Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-(4-cyanophenoxy)phenyl]- | [EINECS(EC#)]
806-020-3 | [Molecular Formula]
C21H13ClF3N3O2 | [MDL Number]
MFCD27665015 | [MOL File]
1313019-65-6.mol | [Molecular Weight]
431.8 |
| Hazard Information | Back Directory | [Uses]
STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. STAT3-IN-7 induces cell apoptosis through SHP-1 dependent STAT3 inactivation. STAT3-IN-7 does not inhibit kinase activity and has anticancer effects[1]. | [Biological Activity]
SC-1 is a derivative of the multiple tyrosine kinase inhibitor sorafenib with no kinase-inhibition activity. SC-1 blocks STAT3 phosphorylation and activation with similar potency to sorafeniband induces apoptosis in hepatocellular carcinoma cell lines. | [in vivo]
STAT3-IN-7 (10 mg/kg; oral gavage; daily; for 28 days; female NCr athymic nude mice) treatment shows efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors[1]. | Animal Model: | Female NCr athymic nude mice (4-6 weeks of age) injected with breast cancer cells [1] | | Dosage: | 10 mg/kg | | Administration: | Oral gavage; daily; for 28 days | | Result: | Showed efficacious antitumor activity and p-STAT3 downregulation in MDA-MB-468 xenograft tumors.
|
| [IC 50]
p-STAT3 | [References]
[1] Chun-Yu Liu, et al. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. Breast Cancer Res. 2013;15(4):R63. DOI:10.1186/bcr3457 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|